Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by Fabian Lorenz on June 20th, 2025 | 06:55 CEST

Declaration of war on the pharmaceutical industry? Bayer, Novo Nordisk, and insider tip PanGenomic Health

  • healthtech
  • Biotechnology
  • Pharma

Has US Health Secretary Robert F. Kennedy Jr. declared war on the traditional pharmaceutical industry? That is certainly what former Trump press secretary and current podcaster Anthony Scaramucci seems to think. The reason for this is the complete overhaul of the US Vaccine Advisory Committee. One company set to benefit from the new US Health Secretary is PanGenomic Health. The Company plans to launch a new digital health and alternative medicine business this year. If it manages to secure even a small share of this billion-dollar market, its share price could multiply. The price target for Novo Nordisk was recently reduced. The stock is working on bottoming out, and there was a success for the blockbuster in the US. Bayer's stock is trending favorably. Regular positive news is currently overshadowing the legal disputes in the US. There was recently some positive news to report there.

Read

Commented by Armin Schulz on June 17th, 2025 | 07:25 CEST

Pharmaceutical revolution 2025: Why Novo Nordisk, NetraMark Holdings, and Bayer are doubling their returns through AI efficiency

  • Biotechnology
  • AI
  • Pharma

The pharmaceutical industry is undergoing a digital transformation in 2025. Artificial intelligence is decoding active ingredients in record time, big data is driving personalized therapies, and blockchain is securing supply chains. These technologies are catapulting efficiency skyward and dramatically reducing development costs in a billion-dollar market that is growing steadily due to demographic change. Those who identify the right companies now will benefit from the disruptive wave. Therefore, we look at three companies that could benefit from this change: Novo Nordisk, NetraMark Holdings, and Bayer.

Read

Commented by André Will-Laudien on June 13th, 2025 | 07:00 CEST

The three IT musketeers – AI, high tech, quantum computing! NetraMark Holdings, Bayer, Novo Nordisk, and D-Wave

  • AI
  • hightech
  • computing
  • Pharma
  • Biotechnology

A new edition of GTC 2025 is currently underway in the French capital, Paris, where NVIDIA CEO Jensen Huang spoke at length about the future of artificial intelligence. As usual, he also made some interesting comments about quantum computers. In the eyes of the NVIDIA CEO, quantum computer technology has reached a decisive turning point and will soon be able to solve some interesting problems that would take even NVIDIA's most advanced AI systems years of computing time to solve. The requirements go beyond pattern recognition, automation, and real-time decisions. Recently, AI has also been playing a significant role in medicine and pharmaceutical development. For some stocks, there is, therefore, a daily reason to reach new highs. Now is the time for investors to focus!

Read

Commented by Fabian Lorenz on June 9th, 2025 | 07:15 CEST

BioNTech billion-dollar deal a template for BioNxt Solutions? Bayer shares recommended as a buy!

  • Biotechnology
  • Pharma

The billion-dollar deal between BioNTech and Bristol-Myers Squibb was a real bombshell and has revitalized the biotech industry. While analysts are raising their price targets for the German biotech high-flyer, there are also critical voices. Investors are also wondering where Big Pharma will strike next. One potential candidate for a partnership is BioNxt Solutions. The Company aims to simplify drug administration using oral dissolvable films, skin patches, and tablets. Clinical trials are about to begin on the development of its lead product for the easier treatment of multiple sclerosis, and a key patent has just been granted in Europe. Due to its low valuation and universal application possibilities, a complete takeover is also conceivable. And what is Bayer doing? Despite numerous legal proceedings, the stock is performing well in 2025. Analysts see further upside potential and have upgraded the stock.

Read

Commented by Armin Schulz on June 6th, 2025 | 07:00 CEST

The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?

  • Healthcare
  • Pharma
  • Biotechnology

The US healthcare system is undergoing unprecedented change under Secretary Robert F. Kennedy Jr. Pharmaceutical giants are groaning under drastic price controls and regulatory upheaval, while digital healthcare pioneers are sensing unprecedented opportunities. This systemic shock is tearing down old power structures and catapulting agile players to the forefront – an explosive interplay of risk and opportunity. Those who understand the new rules of the game will discover lucrative prospects amid the chaos. Today, we take a look at Bayer, PanGenomic Health, and Pfizer to see who stands to benefit.

Read

Commented by Nico Popp on June 5th, 2025 | 07:00 CEST

These ESG innovations really exist: Bayer, Deere & Company, Argo Living Soils

  • Agribusiness
  • fertilizer
  • Pharma
  • machinery

Sustainability is anything but boring: Companies such as Bayer and Deere & Company are scoring points with technological innovations that are more reminiscent of Elon Musk and SpaceX than specialists in seeds and agricultural machinery. The small Canadian agricultural company Argo Living Soils has even found a solution to completely revolutionize CO2-intensive processes in construction. We present the business models and take a look at the outlook for the three stocks.

Read

Commented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST

A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark

  • Biotechnology
  • AI
  • Biotech
  • Pharma

Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?

Read

Commented by Armin Schulz on June 2nd, 2025 | 07:10 CEST

Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot

  • Biotechnology
  • Biotech
  • Pharma
  • Oncology

Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.

Read

Commented by Stefan Feulner on May 27th, 2025 | 07:05 CEST

Bayer, Desert Gold, Snowflake – Breakout imminent

  • Mining
  • Gold
  • Pharma
  • cloud
  • computing

US President Donald Trump's tariff hammer against the European Union caused stock markets to falter at the close of the trading week, but the postponement of the measures by four weeks eased tensions over the weekend. As a result, Germany's leading index, the DAX, got off to a flying start to the week, regaining the 24,000-point mark. However, uncertainties remain, meaning the safe haven gold could once again rise to new highs.

Read

Commented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST

Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva

  • Biotechnology
  • Biotech
  • Pharma

In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?

Read